Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021197340 - ANTIBODY AND FUSION PROTEIN FOR TREATING CORONAVIRUSES AND USE THEREOF

Publication Number WO/2021/197340
Publication Date 07.10.2021
International Application No. PCT/CN2021/084069
International Filing Date 30.03.2021
IPC
C07K 16/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 15/13 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
A61K 39/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
42viral
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Applicants
  • 百奥泰生物制药股份有限公司 BIO-THERA SOLUTIONS, LTD. [CN]/[CN]
Inventors
  • 张慧 ZHANG, Hui
  • 汪志炜 WAMG, Zhiwei
  • 陈俊有 CHEN, Junyou
  • 陈振埕 CHEN, Zhencheng
  • 李闯 LI, Chuang
  • 晏庆威 YAN, Qingwei
  • 郑丹丹 ZHENG, Dandan
  • 杨少伟 YANG, Shaowei
  • 李嘉萍 LI, Jiaping
  • 秦超 QIN, Chao
  • 黄贤明 HUANG, Xianming
  • 李胜峰 LI, Shengfeng
  • 黄皓辉 HUANG, Haohui
  • 苏紫琪 SU, Ziqi
Priority Data
202010244894.431.03.2020CN
202010286986.913.04.2020CN
202010287037.213.04.2020CN
202010344084.627.04.2020CN
202010344572.727.04.2020CN
202010784365.306.08.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) ANTIBODY AND FUSION PROTEIN FOR TREATING CORONAVIRUSES AND USE THEREOF
(FR) ANTICORPS ET PROTÉINE DE FUSION POUR TRAITER DES CORONAVIRUS ET LEUR UTILISATION
(ZH) 用于治疗冠状病毒的抗体、融合蛋白及其应用
Abstract
(EN) Provided in the present invention are an antibody and a fusion protein for treating coronaviruses and the use thereof. The 6-HB interference polypeptide in the fusion protein of the present invention and part of an antibody or an antigen-binding fragment work synergistically to prevent the fusion of SARS-CoV or SARS-CoV-2 virus particles with cells, and mediate the phagocytosis and clearance of the virus particles by immune cells.
(FR) La présente invention concerne un anticorps et une protéine de fusion pour traiter des coronavirus et leur utilisation. Le polypeptide d'interférence 6-HB dans la protéine de fusion selon la présente invention et une partie d'un anticorps ou d'un fragment de liaison à l'antigène fonctionnent de manière synergique pour empêcher la fusion de particules du virus SARS-CoV ou SARS-CoV-2 avec des cellules, et induisent la phagocytose et la clairance des particules virales par des cellules immunitaires.
(ZH) 本发明提供用于治疗冠状病毒的抗体、融合蛋白及其应用。本发明融合蛋白中6-HB干扰多肽与抗体部分或抗原结合片段协同阻止SARS-CoV或SARS-CoV-2病毒颗粒和细胞融合,以及介导免疫细胞吞噬、清除病毒颗粒。
Latest bibliographic data on file with the International Bureau